These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17111056)

  • 1. New treatment strategies against hepatitis C viral infection.
    Bilodeau M; Lamarre D
    Can J Gastroenterol; 2006 Nov; 20(11):735-9. PubMed ID: 17111056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
    Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B
    Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates on antiviral therapy for chronic hepatitis C.
    Toniutto P; Fabris C; Bitetto D; Fornasiere E; Rapetti R
    Discov Med; 2007 Feb; 7(37):27-32. PubMed ID: 17343802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus infection management in 2012.
    Van Gulick JJ; Lamers MH; Drenth JP
    Panminerva Med; 2012 Mar; 54(1):1-9. PubMed ID: 22278112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
    Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
    Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical timing and benefit of antiviral treatment for hepatitis C].
    Chen LC; Xie Q
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):164-169. PubMed ID: 28482401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
    Jiménez-Méndez R; Castañeda-Hernández G
    Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Novel methods of hepatitis C treatment and prevention].
    Chmielewska AM; Rychłowska M; Król E; Solarz K; Bieńkowska-Szewczyk K
    Postepy Hig Med Dosw (Online); 2015 Aug; 69():946-63. PubMed ID: 26400881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B; Kovács B; Battyáni Z
    Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hepatitis C: current status and perspectives].
    Pol S; Corouge M
    Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of hepatitis C virus infection].
    Zeuzem S
    Praxis (Bern 1994); 2005 May; 94(18):721-6. PubMed ID: 15938383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
    Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
    Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric hepatitis C infection: to treat or not to treat...what's the best for the child?
    Serranti D; Buonsenso D; Ceccarelli M; Gargiullo L; Ranno O; Valentini P
    Eur Rev Med Pharmacol Sci; 2011 Sep; 15(9):1057-67. PubMed ID: 22013729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hepatitis C: current status and remaining challenges.
    Santantonio T; Wiegand J; Gerlach JT
    J Hepatol; 2008 Oct; 49(4):625-33. PubMed ID: 18706735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.